| dailymed-drugs:688 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:688 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:688 | rdfs:label | ATRIPLA (Tablet, Multilayer) | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:activeIng... | dailymed-ingredient:Efavire... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:boxedWarn... | WARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals [See Warnings and Precautions (5.1)]. ATRIPLA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of ATRIPLA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued EMTRIVA or VIREAD, which are components of ATRIPLA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue ATRIPLA. If appropriate, initiation of anti-hepatitis B therapy may be warranted [See Warnings and Precautions (5.2)]. | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:activeMoi... | dailymed-ingredient:Efavire... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:titaniu... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Magnesi... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:talc | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:polyeth... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:black_i... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Croscar... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Microcr... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:polyvin... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:red_iro... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Sodium_... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Hydroxy... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:inactiveI... | dailymed-ingredient:Opadry_... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:genericMe... | efavirenz, emtricitabine, and tenofovir disoproxil fumarate | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:fullName | ATRIPLA (Tablet, Multilayer) | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:688 | dailymed-instance:name | ATRIPLA | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:688 | lld:dailymed |
